Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 315980, 6 pages
Research Article

Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia

1Biological Sciences Department, College of Science, King Faisal University, Hofouf 31982, Saudi Arabia
2Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece

Received 28 October 2012; Revised 17 January 2013; Accepted 3 February 2013

Academic Editor: M. Ilyas Kamboh

Copyright © 2013 Abdullah M. Alzahrani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Polymorphisms in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence the dose variability of coumarinic oral anticoagulants (COAs). Substantial inter- and intraethnic variability exists in the frequencies of CYP2C92 and 3 and VKORC1 –1639A alleles. However, the prevalence of CYP2C9 and VKORC1 genetic variants is less characterized in Arab populations. A total of 131 healthy adult subjects from the Al-Ahsa region of Saudi Arabia were genotyped for the CYP2C92 and 3 and VKORC1 –1639G>A polymorphisms by PCR-RFLP method. The frequencies of the CYP2C92 and 3 and VKORC1 –1639A alleles were 13.3%, 2.3%, and 42.4%, respectively, with no subjects carrying 2 defective alleles. The frequencies of the CYP2C93 and VKORC1 –1639A alleles were significantly lower than those reported in different Arabian populations. None of the subjects with the VKORC1 –1639AA genotype were carriers of CYP2C91/3 genotypes that lead to sensitivity to COAs therapy. The low frequency of the CYP2C93 allele combined with the absence of subjects carrying 2 defective CYP2C9 alleles suggests that, in this specific population, pharmacogenetic COAs dosing may mostly rely upon VKORC1 genotyping.